On July 31, 2023, the U.S. Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) for primary advanced or recurrent endometrial…
On August 2, 2023, the U.S. Food and Drug Administration approved trifluridine and tipiracil (LONSURF) with bevacizumab for the treatment…
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr.…
On June 20, 2023, the U.S. Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) in combination with enzalutamide for…
On July 20, 2023, the U.S. Food and Drug Administration (FDA) approved quizartinib (Vanflyta) for adult patients newly diagnosed with…
On June 15, 2023, the U.S. Food and Drug Administration approved Glofitamab-gxbm (Columvi) for the treatment of adult patients with…
X-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam…
By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant,…
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Hodgkin’s lymphoma (HL) has had an exciting and…
Imetelstat in low-risk MDS for transfusion independence By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center …